Zonisamide has been used in the management of epilepsy in Japan for three decades. After further controlled trials it was approved by the Federal Drug Administration for use in the United States in 2000, and by the European Medicines Agency as an adjunctive therapy for epilepsy in 2010, obtaining a monotherapy licence in 2012. More recently it has been adopted for use by headache specialists treating migraine [1]. It is a sulphonamide, and acts via a broad mechanism of action. It is believed to primarily exert its anti-convulsant effects by blocking sustained, repetitive neuronal firing of voltage-sensitive sodium channels and by reducing voltage-sensitive T-type Calcium channels [2].
11
JUL
JUL
0